Sangamo Therapeutics Inc (SGMO)
OTCHealth CareBiotechnologySnapshot 2026-09-04
$0.07+4.22%
Close 2026-07-28 · 1-day change
OTCHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SGMO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -79.2% |
| Our one-year growth estimate | diamond | -60.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 19.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of — · Company calendar date is not available
SGMO — legal / regulatory event — Bankruptcy or Receivership
Dated 2026-08-28
Bankruptcy or Receivership. As previously announced, on June 23, 2026, Sangamo Therapeutics, Inc. (the “Company”) filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), thereby commencing a Chapter 11 case for the Company (the “Chapter 11 Case”). The case number is 26-10989 and the Chapter 11 Case is styled as In re Sangamo Therapeutics , I…
Why it matters: Lower expenses would show progress towards the goal of reducing costs in 2026.
Supportive ifQ2 operating costs were under $100M.
Worry ifQ2 operating costs were over $120M.
Why it matters: Updates on cash runway will show if Sangamo can pay for operations and projects.
Watch forManagement says cash is enough to fund operations until Q3 2026.
Also watch forManagement says cash will run out before Q3 2026.
Why it matters: More layoffs may mean bigger financial problems. This could hurt how the company operates.
Worry ifMore job cuts are announced. This is in addition to the first 40%.
Less concerning ifNo new job cuts are announced. This shows the company is stable.
Why it matters: Updates on cash and funding are important for operations and growth.
Worry ifThe company says it has secured more funding to extend its cash runway.
Less concerning ifThe company warns of insufficient cash to fund operations beyond the third quarter of 2026.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$0 on $10,000 · ±0.0% | How much price usually moves either way. |
| Bad day | Not available | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,017 loss on $10,000 · 70.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A rebound in sector growth could help Sangamo's performance.
Watch forHealth Care sector revenue growth re-accelerates back toward its highs.
Also watch forSector revenue growth is slowing down.
Why it matters: Job cuts and restructuring may lower efficiency. They could also hurt employee morale.
Worry ifCompleting the job cuts with little impact on ongoing projects is a positive sign.
Less concerning ifBig operational issues or bad employee feedback after the cuts are a negative sign.
Why it matters: Getting funding is key for Sangamo to keep its operations and programs going.
Supportive ifA press release announcing a successful funding round or partnership.
Worry ifIf no funding is secured by Q3 2026, there will be operational issues.
Why it matters: This study will show how well ST-503 can treat chronic neuropathic pain. This could affect future development.
Watch forPositive results from the STAND study showing efficacy for ST-503.
Also watch forThe STAND study had negative results. It shows that ST-503 does not work.
Why it matters: Steady revenue above this level shows management's growth plans are working. This could help investors feel better.
Supportive ifRevenue over $5M for two straight quarters.
Worry ifRevenue under $1.4M for two straight quarters.
Why it matters: Good feedback could speed up the approval for ST-920.
Supportive ifA press release shows positive feedback from the FDA on the ST-920 submission.
Worry ifNegative feedback or requests for additional data from the FDA.
Why it matters: Completing the BLA submission is key for ST-920's approval. This could boost investor confidence.
Supportive ifThe rolling BLA submission for ST-920 is completed by summer 2026.
Worry ifThe BLA submission for ST-920 is delayed beyond summer 2026.
Why it matters: If expenses exceed this amount, it shows management is struggling to cut costs. This could hurt investor confidence.
Worry ifOperating costs above $120M in any quarter of 2026.
Less concerning ifOperating costs below $100M in any quarter of 2026.
Why it matters: Getting funding is important for Sangamo to keep working and support its projects. Not enough funding can cause problems.
Worry ifThe company says it has secured a big funding round or partnership.
Less concerning ifThe company says it is having trouble getting funding, which may lead to cuts.
Why it matters: The restructuring may change how the company operates and how employees feel.
Worry ifThere is good news about efficiency. Employee morale is up after the changes.
Less concerning ifReports of ongoing issues or further layoffs due to the restructuring.
Why it matters: The appeal outcome affects Sangamo's market access and how investors see it.
Watch forA successful appeal can bring Sangamo back to Nasdaq or a good outcome on June 9, 2026.
Also watch forThe appeal is denied, leading to continued trading on the OTCQB Venture Market.